Warning Letter — Amgen Inc.
The FDA's Office of Prescription Drug Promotion (OPDP) issued a Warning Letter to Amgen Inc. on August 12, 2026, regarding promotional activities or materials.
Amgen Inc., regulatory affairs professionals specialized in drug promotion, and commercial compliance teams within the pharmaceutical industry.
OPDP enforcement actions typically signal that promotional materials have failed to meet regulatory standards, such as those governing the balance of risk and benefit information or the substantiation of efficacy claims. This indicates a need for heightened scrutiny of promotional review workflows to prevent potential misbranding or misleading communications.
Review current promotional materials against approved labeling to ensure all claims are substantiated and consistent with indicated uses. Regulatory and legal teams should verify that promotional messaging does not omit material information or misrepresent safety/efficacy data.
FDA Warning Letter issued to: Amgen Inc.. 08/12/2026 — The Office of Prescription Drug Promotion (OPDP). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amgen-inc-739641-08122026
Open in openFDA / FDA.gov